These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 17015884

  • 1. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
    Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA.
    J Clin Oncol; 2006 Oct 20; 24(30):4888-94. PubMed ID: 17015884
    [Abstract] [Full Text] [Related]

  • 2. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
    Jara Sánchez C, Ruiz A, Martín M, Antón A, Munárriz B, Plazaola A, Schneider J, Martínez del Prado P, Alba E, Fernández-Aramburo A.
    Breast Cancer Res Treat; 2007 Jan 20; 101(2):215-23. PubMed ID: 16823507
    [Abstract] [Full Text] [Related]

  • 3. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B, Jeong JH, Anderson S, Wolmark N.
    J Natl Cancer Inst; 2004 Dec 15; 96(24):1823-31. PubMed ID: 15601638
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    Breast Cancer Res Treat; 2009 Jul 15; 116(1):153-60. PubMed ID: 18787948
    [Abstract] [Full Text] [Related]

  • 5. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P.
    J Natl Cancer Inst; 2005 Dec 07; 97(23):1724-33. PubMed ID: 16333028
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 7. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    International Breast Cancer Study GroupCSL Ltd, 45 Poplar Rd,Parkville, Vic 3052, Australia. russell.basser@csl.com.au, Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A.
    J Clin Oncol; 2006 Jan 20; 24(3):370-8. PubMed ID: 16421418
    [Abstract] [Full Text] [Related]

  • 8. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y, Xu BH, Li Q, Zhang P, Zhao LM, Yuan P, Wang JY.
    Zhonghua Yi Xue Za Zhi; 2008 Jan 08; 88(2):77-81. PubMed ID: 18353207
    [Abstract] [Full Text] [Related]

  • 9. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
    Cheng YC, Rondón G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT.
    Biol Blood Marrow Transplant; 2004 Nov 08; 10(11):794-804. PubMed ID: 15505610
    [Abstract] [Full Text] [Related]

  • 10. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y.
    J Clin Oncol; 2009 Mar 20; 27(9):1368-74. PubMed ID: 19204202
    [Abstract] [Full Text] [Related]

  • 11. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.
    Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS.
    Breast; 2008 Dec 20; 17(6):646-53. PubMed ID: 18595699
    [Abstract] [Full Text] [Related]

  • 12. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group.
    J Natl Cancer Inst; 2007 Apr 04; 99(7):506-15. PubMed ID: 17405995
    [Abstract] [Full Text] [Related]

  • 13. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.
    Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Yen Y, Damon L, Doroshow JH.
    J Clin Oncol; 2004 May 15; 22(10):1839-48. PubMed ID: 15143076
    [Abstract] [Full Text] [Related]

  • 14. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2008 Apr 01; 14(7):2082-7. PubMed ID: 18381948
    [Abstract] [Full Text] [Related]

  • 15. Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes.
    Wright JL, Cordeiro PG, Ben-Porat L, Van Zee KJ, Hudis C, Beal K, McCormick B.
    Int J Radiat Oncol Biol Phys; 2008 Jan 01; 70(1):43-50. PubMed ID: 17855006
    [Abstract] [Full Text] [Related]

  • 16. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
    Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL.
    J Clin Oncol; 2006 Nov 01; 24(31):4956-62. PubMed ID: 17075113
    [Abstract] [Full Text] [Related]

  • 17. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
    Secord AA, Havrilesky LJ, O'Malley DM, Bae-Jump V, Fleming ND, Broadwater G, Cohn DE, Gehrig PA.
    Gynecol Oncol; 2009 Sep 01; 114(3):442-7. PubMed ID: 19560193
    [Abstract] [Full Text] [Related]

  • 18. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R, European Organisation for Research and Treatment of Cancer Breast Group, Scottish Breast Cancer Trials Group.
    Eur J Cancer; 2007 Jan 01; 43(2):331-40. PubMed ID: 17134892
    [Abstract] [Full Text] [Related]

  • 19. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
    Toledano A, Azria D, Garaud P, Fourquet A, Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O, Calais G.
    J Clin Oncol; 2007 Feb 01; 25(4):405-10. PubMed ID: 17264336
    [Abstract] [Full Text] [Related]

  • 20. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.